Bicycle Therapeutics (NASDAQ:BCYC) COO Alistair Milnes Sells 3,244 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,244 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $6.80, for a total value of $22,059.20. Following the completion of the sale, the chief operating officer owned 140,133 shares of the company’s stock, valued at $952,904.40. This represents a 2.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Alistair Milnes also recently made the following trade(s):

• On Monday, January 5th, Alistair Milnes sold 3,416 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total value of $22,067.36.

Bicycle Therapeutics Price Performance

Shares of Bicycle Therapeutics stock traded down $0.04 during trading on Tuesday, hitting $6.57. 259,093 shares of the company were exchanged, compared to its average volume of 215,285. The firm has a market capitalization of $455.76 million, a P/E ratio of -1.81 and a beta of 1.52. The firm’s fifty day moving average price is $6.97 and its 200 day moving average price is $7.42. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $6.03 and a 1-year high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.24. The business had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. As a group, equities research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on BCYC. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company. Citizens Jmp increased their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday, October 31st. JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Hold” and an average target price of $19.73.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Assetmark Inc. raised its position in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Bicycle Therapeutics by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock worth $976,000 after acquiring an additional 2,243 shares during the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Bicycle Therapeutics by 32.6% during the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after acquiring an additional 2,659 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after acquiring an additional 2,668 shares in the last quarter. Finally, Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter valued at approximately $70,000. 86.15% of the stock is currently owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.